Revenue: As of FY2025, the actual value is USD 19.19 M, beating the estimate of USD 19.17 M.EPS: As of FY2025, the actual value is USD -1.09, missing the estimate of USD -1.08.EBIT: As of FY2025, the actual value is USD -2.197 M.<h3>Segment Revenue</h3><ul><li>Total Net Sales: $19,190,468 for fiscal year ended September 30, 2025, compared to $19,482,167 for fiscal year ended September 30, 2024, representing a decrease of $291,699.</li><li>E-commerce Sales: $14,713,380 (76.7% of total) for fiscal year ended September 30, 2025, compared to $15,655,337 (80.4% of total) for fiscal year ended September 30, 2024.</li><li>Wholesale Sales: $4,477,088 (23.3% of total) for fiscal year ended September 30, 2025, compared to $3,826,830 (19.6% of total) for fiscal year ended September 30, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Operating Loss: $2,162,590 for fiscal year ended September 30, 2025, compared to $3,315,410 for fiscal year ended September 30, 2024, showing an improvement of $1,152,820.</li><li>Net Loss: $2,040,902 for fiscal year ended September 30, 2025, compared to $3,700,126 for fiscal year ended September 30, 2024, showing an improvement of $1,659,224.</li><li>Gross Profit: $11,968,255 for fiscal year ended September 30, 2025, compared to $11,995,541 for fiscal year ended September 30, 2024.</li><li>Gross Margin: 63.0% for fiscal year ended September 30, 2025, compared to 61.6% for fiscal year ended September 30, 2024.</li></ul><h3>Cash Flow</h3><ul><li>Cash and Cash Equivalents: $2,261,242 as of September 30, 2025, compared to $2,452,553 as of September 30, 2024.</li><li>Operating Cash Flow: Net cash used by operating activities was $1,452,375 for fiscal year ended September 30, 2025, compared to $352,792 for fiscal year ended September 30, 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Inventory Write-downs: $365,979 during fiscal year ended September 30, 2025, primarily related to obsolete and expired stock keeping units.</li></ul><h3>Outlook / Guidance</h3>cbdMD anticipates continued momentum in its direct-to-consumer business and wholesale channels, with additional distribution for its Oasis brand. The company has identified nearly $200,000 in corporate overhead savings to be implemented in early 2026. However, federal regulatory changes pose a significant threat to the industry and could impact approximately 40-45% of the company’s revenue derived from full spectrum SKUs.

cbdMD | 10-K: FY2025 Revenue Beats Estimate at USD 19.19 M